ClinicalTrials.gg
Not yet recruitingNCT07853157Updated Oct 1, 2026

AI-Assisted 3D Reconstruction for Lung Resection Planning

An observational study in Lung Cancer, Artifical Intelligence and Surgery for Primary Lung Cancer, sponsored by S. Andrea Hospital. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by S. Andrea Hospital · Observational

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 300 studies in Lung Neoplasms with a site in Italy — 87 open to participants now, 116 under way, 24 of them phase 3. Lung Neoplasms · Italy.

Planned enrollment
78th of 91
50 · median 200
Started
2026
with 14 others
Observational
91 of 300
39 open now
Primary completion
2027-05
later than 59 of 115 live
Registered
299th of 300
by date

Among the 300 studies in Lung Neoplasms with a site in Italy, this one is the 78th largest by planned enrollment of the 91 observational ones that give a count, is one of 15 that started in 2026, is one of 91 observational ones, reaches primary completion later than 59 of the 115 other live ones, and was the 299th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

87 of the 300 studies in Lung Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 300 studies in Lung Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

This prospective observational study aims to validate an artificial intelligence (AI)-based system for automated three-dimensional (3D) reconstruction of pulmonary anatomy from preoperative chest computed tomography (CT) scans in patients undergoing lung resection.

The AI system will automatically identify and reconstruct relevant pulmonary anatomical structures, including pulmonary arteries, veins, bronchi, lobes, and segments. AI-generated 3D reconstructions will be compared with expert manual 3D reconstructions and with anatomical findings documented during surgery.

The primary objective is to assess the anatomical accuracy of AI-generated 3D reconstructions in identifying surgically relevant bronchovascular anatomy and anatomical variants. Secondary objectives include evaluating accuracy for individual anatomical structures, discrepancies between automated and manual reconstructions, concordance with intraoperative findings, and the time required to generate and review the automated reconstruction.

The study is observational and will not modify the planned surgical procedure or standard patient care.

Read the detailed description

Patients scheduled for anatomical lung resection who meet the study eligibility criteria will be prospectively enrolled. Preoperative contrast-enhanced chest CT images acquired as part of routine clinical care will be used for 3D reconstruction.

For each patient, an AI-based segmentation system will generate a 3D reconstruction of the relevant pulmonary anatomy, including pulmonary arterial, venous and bronchial structures, as well as lobar and segmental anatomy when applicable. The automated reconstruction will be reviewed without modifying the planned surgical treatment.

AI-generated reconstructions will be compared with expert manual 3D reconstructions and with anatomical findings documented intraoperatively. Particular attention will be given to the identification of surgically relevant bronchovascular branches and anatomical variants.

The primary analysis will assess the proportion of patients in whom the AI-generated reconstruction accurately represents all predefined surgically relevant anatomical structures for the planned resection, without clinically relevant omissions or incorrect structures.

Secondary analyses will assess performance at the individual anatomical-structure level, including arterial, venous and bronchial structures; characterize errors and discrepancies between automated and manual reconstruction; evaluate concordance with intraoperative anatomy; and assess the time required for automated reconstruction and expert review.

The study is a prospective, single-center observational validation study. All diagnostic and therapeutic decisions, including the indication and type of lung resection, will be made according to standard clinical practice independently of study participation.

03

Conditions studied

  • Lung Cancer
  • Artifical Intelligence
  • Surgery for Primary Lung Cancer

Browse trials for

Keywords

  • Artificial Intelligence
  • Three-Dimensional Reconstruction
  • Lung Resection
  • Thoracic Surgery
  • Preoperative Planning
  • Pulmonary Anatomy
  • Image Segmentation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients undergoing anatomical lung resection at the Thoracic Surgery Unit of Sant'Andrea University Hospital who have a preoperative contrast-enhanced chest CT scan suitable for AI-based 3D reconstruction.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Scheduled for anatomical lung resection (segmentectomy, lobectomy, bilobectomy, or pneumonectomy)
  • Availability of a preoperative contrast-enhanced chest CT scan suitable for 3D reconstruction, with slice thickness ≤1.5 mm.
  • Ability to provide .

Exclusion criteria

Exclusion Criteria:

  • Preoperative CT images of insufficient quality or technical characteristics for 3D reconstruction.
  • Cancellation of the planned surgical procedure before surgery.
  • Inability or unwillingness to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prospective Validation Cohort

    Patients undergoing lung resection who are prospectively enrolled for validation of the AI-based 3D reconstruction system. Preoperative CT images will be processed by the AI system, and the resulting 3D reconstructions will be compared with expert manual reconstruction and intraoperative anatomical findings.

    Other: AI-Based 3D Reconstruction

Interventions

  • OtherAI-Based 3D Reconstruction

    Preoperative contrast-enhanced chest CT images will be processed using an artificial intelligence-based segmentation system to automatically generate three-dimensional reconstructions of pulmonary anatomy, including pulmonary arteries, veins, bronchi, lobes, and segments when applicable. The AI-generated reconstructions will be evaluated against expert manual 3D reconstruction and intraoperative anatomical findings. The AI output will not determine or modify the planned surgical treatment.

06

What researchers measure

Primary outcomes

  1. Patient-Level Anatomical Accuracy of AI-Generated 3D Reconstruction

    Proportion of patients in whom the AI-generated 3D reconstruction correctly represents all predefined surgically relevant pulmonary arterial, venous, and bronchial structures and anatomical variants for the planned lung resection, without clinically relevant omissions or incorrectly represented structures. Accuracy will be assessed by comparison with expert manual 3D reconstruction and intraoperative anatomical findings.

    Time frame: From preoperative CT imaging through completion of the surgical procedure

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2027, 5 months later.

Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 5 months is below that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Oct 1, 2026
StartEst.
Nov 2, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07853157
Lead sponsor
S. Andrea Hospital
Responsible party
Giacomo Argento (Thoracic Surgeon, S. Andrea Hospital) — Principal investigator
First posted
Oct 1, 2026
Start date
Nov 2, 2026 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Oct 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion